Evidence map›Paper›PMID 40731782›Full record

Observational studyMedicina (Kaunas, Lithuania)2025

Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study.

Deniz Çetin, Elif Bilgili, Ömer Komaç, Merve Yetişken, Engin Güney

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Deniz ÇetinDepartment of Endocrinology and Metabolism, Faculty of Medicine, Aydın Adnan Menderes University, Aydın 09000, Turkey.ORCID 0000-0001-9144-4018
Elif BilgiliDepartment of Endocrinology and Metabolism, Faculty of Medicine, Aydın Adnan Menderes University, Aydın 09000, Turkey.
Ömer KomaçDepartment of Endocrinology and Metabolism, Faculty of Medicine, Aydın Adnan Menderes University, Aydın 09000, Turkey.
Merve YetişkenDepartment of Endocrinology and Metabolism, Faculty of Medicine, Aydın Adnan Menderes University, Aydın 09000, Turkey.
Engin GüneyDepartment of Endocrinology and Metabolism, Faculty of Medicine, Aydın Adnan Menderes University, Aydın 09000, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Benzhydryl CompoundsBody CompositionDiabetes Mellitus, Type 2GlucosidesMuscle StrengthSarcopeniaAgedFemaleHand StrengthHumansMaleMiddle AgedSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorsbody compositionempagliflozinmuscle strengthsarcopeniaSGLT2 inhibitorstype 2 diabetes

Identifiers

PMID40731782
PMCPMC12299443

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.